LY-674 is primarily investigated for its potential in immunomodulatory therapies. It functions as a selective inhibitor of certain inflammatory pathways, making it a candidate for treating autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Research indicates it may suppress overactive immune responses by targeting specific signaling proteins involved in cytokine production, thereby reducing tissue inflammation and damage. It is also being explored in oncology for its ability to enhance anti-tumor immunity by modulating the tumor microenvironment. Due to its targeted mechanism, LY-674 shows promise in minimizing broad immunosuppressive effects, which could lead to fewer side effects compared to conventional therapies. Currently, it remains under preclinical and early clinical evaluation.